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Sleeping Beauty transposase structure allows
rational design of hyperactive variants for genetic
engineering
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Sleeping Beauty (SB) is a prominent Tc1/mariner superfamily DNA transposon that provides a
popular genome engineering tool in a broad range of organisms. It is mobilized by a
transposase enzyme that catalyses DNA cleavage and integration at short specific sequences
at the transposon ends. To facilitate SB’s applications, here we determine the crystal structure
of the transposase catalytic domain and use it to model the SB transposase/transposon
end/target DNA complex. Together with biochemical and cell-based transposition assays,
our structure reveals mechanistic insights into SB transposition and rationalizes previous
hyperactive transposase mutations. Moreover, our data enables us to design two additional
hyperactive transposase variants. Our work provides a useful resource and proof-of-concept
for structure-based engineering of tailored SB transposases.
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T
ransposons are natural DNA-mobilizing vehicles that have
an intrinsic ability for genomic integration. In contrast
to other genome engineering tools, such as zinc-finger
nucleases, TALENs or the CRISPR/Cas9 system, transposons
directly insert their genetic cargo into genomes, and can thereby
enable stable gene transfer with high efficiency potentially
alleviating the need for clonal selection in medical applications.
SB is a member of the widespread Tc1/mariner superfamily of
DNA transposons that has been developed as a genome
engineering tool in a broad range of organisms1,2. It offers up
to 95% gene transfer efficiency in diverse vertebrate cell types and
is widely used in forward genetic screens3,4 as well as in ex vivo
human gene therapy trials5,6. The transposon (tnp) DNA includes
terminal inverted repeats (TIRs) at its ends and encodes a
transposase protein, the workhorse of transposition, that catalyses
all DNA cleavage and joining reactions required for transposition.
Structural and biochemical studies of model Tc1/mariner
transposons (Tc3, Mos1 and HsMar1)7–9 revealed a so-called
cut-and-paste mechanism that involves: (i) transposase binding to
the TIRs; (ii) synapsis of the tnp ends generating an intertwined
nucleoprotein complex, the paired-end complex (PEC) (also
called transpososome); (iii) coordinated stepwise cleavage of the
two DNA strands on both tnp ends; (iv) target DNA (tDNA)
binding via recognition of a TA dinucleotide; and (v) integration
into the new genomic location. Integration occurs with a
two-base-pair (bp) stagger at each side of the target TA and
results in single-strand gaps on both transposon flanks that are
repaired subsequently by host enzymes leading to characteristic
target site duplication.
Tc1/mariner transposases contain an N-terminal bipartite
PAIRED-like10 DNA-binding domain (DBD) consisting of two
helix-turn-helix motifs, and a C-terminal catalytic domain
with an RNaseH-like fold and a catalytic triad of three acidic
residues (DDE)1 that execute DNA hydrolysis (in excision) and
transesterification (in integration) in a two metal ion-dependent
manner11,12. Well-studied Tc1/mariner transposases (for example,
Mos1 and HsMar1) function as homodimers that likely
undergo multiple conformational rearrangements throughout the
transposition reaction7,8,13–15. They initially assemble as auto-
inhibited dimers, which rearrange upon DNA binding to allow
hydrolysis of the first DNA strand (non-transferred strand, NTS)
2–3 nucleotides (nt) inside the tnp on both ends8,14. Subsequently,
the transpososome changes conformation to bring the second
DNA strand (transferred strand, TS) into the transposase active
site7,8,15 for cleavage at the exact tnp boundary. Finally, tDNA
capture might induce further conformational changes, but since
the post-TS-cleavage transpososome already holds the terminal
30OH groups of the TS in the transposase active sites, no major
rearrangements seem to be required to proceed to integration.
From all the distinct nucleoprotein assemblies, high-resolution
structural information is so far only available for the Drosophila
mauritiana Mos1 pre-16 and post-TS-cleavage7 PECs, both of
which contain the TS ends in the transposase active sites. These
highly similar structures depict the tnp ends in a parallel
arrangement with the 30OH ends of the TS-s situated 24.8Å
from each other. This arrangement appears consistent with a
concerted attack of the two tnp ends on the tDNA with a 2-bp
stagger7, although the 30OH groups are somewhat far, suggesting
that the tDNA may need to be bent for efficient integration. In
accordance, bent tDNA has been shown to be a preferred target for
integration of Tc1/mariners17–19, including SB20,21 and might even
be a general feature of DDE enzymes22,23.
The 39 kDa SB transposase (340 amino acids (aa)) features a
similar domain composition to other Tc1/mariner transposases.
However, it has limited (o20%) sequence identity to its relatives
and includes sub-domains with unknown functions, such as the
glycine-rich strip1 (aa 183–198) that is specific to the Tc1
subfamily at the base of the so-called clamp loop (aa 159–190)7.
SB’s transposon end architecture is also unusual: while the
mariner transposons HsMar1 and Mos1 contain short 30–40 bp
almost perfect inverted repeats, SB’s TIRs are B230 bp long and
contain two 30–35 bp highly conserved transposase binding sites
placed in a direct repeat (IR/DR) orientation separated
by DNA segments of variable sequence1. To date, little
biochemical data is available for the SB transposon and
structural information is limited to the N-terminal HTH-motif
of the transposase DBD24. To facilitate SB’s applications in
genetic engineering, several hyperactive transposase variants
have been developed2,25–27, providing up to 100-fold increased
efficiencies. However, the activity of the transposase is cell type
dependent28 and several applications, including gene transfer into
medically relevant primary human cells, would greatly benefit
from further enhanced transposase variants. However, rational
engineering of novel SB variants is currently hampered by the
lack of specific mechanistic and structural data, particularly for
the transposase catalytic domain. To overcome this limitation,
here we solve the first crystal structure of the SB catalytic domain
and, based on this, generate a model of the SB transpososome
containing transposon end as well as target DNA. The
acquired structural insights enable us to rationalize previous
hyperactive mutations on the transposase as well as design novel
defective and hyperactive SB variants. Our work provides
novel insights into SB’s mechanism and demonstrates how
structure-based design can help generate further designer
transposases.
Results
The structure of the SB100X catalytic domain. To provide
structural insights into SB transposition, we crystallized the
catalytic domain (aa 114–340; including most of the flexible inter-
domain linker that spans aa 110–127) of the current most active
SB transposase variant2, SB100X, and solved its structure at 1.4 Å
resolution (Fig. 1a, Supplementary Fig. 1 and Table 1). The core
of the structure reveals a canonical RNaseH-fold, consisting of a
central five-stranded b-sheet (b1–b5) surrounded by five
a-helices (a1–a5). The catalytic residues (D153, D244 and
E279, red in Fig. 1a) are assembled in close proximity
establishing an active site conformation similar to the one
observed in the crystal structure of the homologous Mos1
transposase PEC (grey in Figs 1a,b)7.
In addition to the core RNaseH domain, most of the inter-
domain linker (aa 117–127) and also the flexible clamp loop (aa
159–190), which is inserted between b1 and b2 of the RNaseH-
fold7 and includes part of the glycine-rich strip (aa 183–190)1, are
visible in the structure. While the RNaseH core superposes closely
with that of Mos1 in the PEC (r.m.s.d. 1.97Å for Ca atoms,
Fig. 1b) the linker and the clamp loop assume different
conformations (Supplementary Fig. 2). In the Mos1 PEC, the
clamp loop is extended and interacts with the similarly extended
linker and both tnp ends across the dimer interface, playing an
important role in PEC assembly7. In turn, in our SB100X catalytic
domain crystals, the clamp loop is curved (Fig. 1a and
Supplementary Fig. 2b), mostly pivoting on three consecutive
G-s (aa 188–190, marked with red arrow in Fig. 1a) in the
glycine-rich strip, and contributes to an extended protein–protein
interface (2,350Å2 surface area; DG¼  27.2 kcalmol 1)29
between symmetry related molecules in neighbouring
asymmetric units (Fig. 1b,c and Supplementary Fig. 3). This
interface brings two catalytic domains into close proximity with
their active sites facing each other in an arrangement that
resembles the one in the Mos1 PEC7 (Fig. 1b), but is more
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compact and features several additional tight sequence-specific
interactions (Fig. 1d,e and Supplementary Fig. 3g,h). The clamp
loops of both protomers form reciprocal interactions with the
RNaseH core of the partner molecule, covering the active sites
(Fig. 1c,d and Supplementary Fig. 2b). In addition, the tip of the
clamp loop contains two short antiparallel b-strands (aa 169–171
and 174–176), which form a b-hairpin and interact with the main
chain of the inter-domain linker (aa 119–122) of the partner
molecule (Fig. 1e and Supplementary Fig. 3g). This contact
resembles the b-stranded clamp loop—linker interaction
observed in the Mos1 PEC, but involves a different part of the
linker, which is structurally equivalent to the regulatory
WVPHEL motif of mariner transposases15,16,30.
To investigate the functional relevance of the observed
interface, we mutated amino acids N280 and K339 on the
RNaseH core (Fig. 1d) and assessed the effects in transposition
assays in HeLa cells (Fig. 1f and Supplementary Fig. 4). These
amino acids were selected for mutagenesis, because they are
critical to the newly observed interface, but localize distant from
the intermolecular interface in the PEC and have not been
attributed a functional role before. We find that simultaneous
mutation of both residues strongly reduces transposition
(P¼ 1.7 10 4; t-test), indicating that their combined interac-
tions are required for efficient transposition (Fig. 1f). However, as
the observed arrangement of the catalytic domains is too compact
to allow DNA to access the active sites (Fig. 1b), it does not
appear compatible with PEC assembly. Instead, it might mediate
the formation of a pre-catalytic dimer that must still undergo
conformational rearrangement upon PEC formation (illustrated
by the arrow in Fig. 1b).
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Figure 1 | The structure of the SB100X transposase catalytic domain. (a) The SB100X catalytic domain (blue) assumes an RNaseH-fold with all catalytic
residues (red) assembled in the active site. Conserved a-helices (a) and b-strands (b) are indicated. Insert: superposition of active-site residues in SB100X
and Mos1 (grey, PDB 3HOS)6. (b) The SB100X dimer (dark and light blue) observed in our crystal structure (molecules I and II) superposed onto the Mos1
PEC structure (grey). Arrow illustrates the rearrangement (B50 swing to left with B20 rotation backwards) that can bring Molecule I into the PEC
conformation. (c) Top view of the SB100X catalytic domain dimer highlights the role of the clamp loops in the interaction. (d) Residues N280 and K339 of
the RNaseH core form sequence-specific interactions (hydrogen bonds indicated with dashed lines) with the clamp loops of the partner molecules,
anchoring them to cover the active sites. Insert: close-up of the dimer contacts mediated by N280 and K339, respectively. (e) b-stranded interactions
between the backbones of the clamp loop and the inter-domain linker. (f) Transposition assay for N280A and K339A mutants in HeLa cells. D3 indicates
the negative control using a catalytically inactive transposase mutant, E279D. Error bars represent the means±s.e.m. of three independent experiments.
Statistical analysis was performed by a one-sample t-test and P values are as follows: N280A, 0.061; K339A, 0.34; and N280A/K339A, 1.7 104.
Table 1 | X-ray crystallographic data collection and
refinement statistics.
Data collection
Space group I 21 21 21
Cell dimensions
a, b, c (Å) 84.24, 113.98, 144.94
a, b, g () 90, 90, 90
Resolution (Å) 50–1.4 (1.50–1.40)*
Rsym 0.081 (1.707)
I/sI 17.9 (2.0)
Completeness (%) 100.0 (100.0)
Redundancy 11.2 (11.2)
No. unique reflections 136,613 (25,318)
CC(1/2) 1 (0.694)
Refinement
Resolution (Å) 50–1.4
No. reflections, all/free set 136,607/6,830
Rwork/Rfree 0.171/0.195
No. atoms
Protein 3,782
Ligand/ion 219
Water 721
B-factors 25.40
Protein 22.40
Ligand/ion 39.60
Water 36.80
R.m.s deviations
Bond lengths (Å) 0.020
Bond angles () 1.91
*Highest resolution shell is shown in parenthesis.
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The SB transposase/tnp end/tDNA complex model. To evaluate
and exploit the predictive value of our SB100X structure for
mechanistic studies and protein engineering, we next aimed to
place it into the functionally relevant context by modelling the SB
tDNA capture complex (TCC), which contains the full-length
transposase in complex with tnp end and target DNA (Fig. 2a).
Since an intact TCC structure is so far not available for any
Tc1/mariner transposon, we used the Mos1 PEC structure7 to
model the SB100X PEC (combining a homology model of the
DNA-binding domains with the catalytic domain coordinates
determined here), and docked a bent tDNA substrate derived
from the prototype foamy virus (PFV) intasome structure23 into
the positively charged cleft formed at the base of the catalytic
domains (Fig. 2b).
We used a bent tDNA for our modelling, as previous
biochemical and structural data have indicated that Tc1/mariners
require significant target bending for efficient integration16–18,21,
a feature that seems to be broadly conserved among DDE
enzymes22,23,31. In accordance, the tDNA-binding groove in the
SB100X TCC model has an inward arc with the active sites
situated at the bottom (Fig. 2b) and cannot fit a straight B-form
DNA without major clashes. In turn, the kinked PFV tDNA fits
well in the cleft with its sugar-phosphate backbones delving into
the active sites. In the resulting TCC model the two tnp ends are
arranged in parallel, with the 30OH groups of the TS approaching
the phosphate groups flanking the central TA on opposite strands
of the tDNA (P-O distances: 4.8 and 5.3 Å, Fig. 2c).
The SB TCC model rationalizes previous hyperactive mutations.
Using the TCC model, we first aimed to rationalize previous
mutations within the SB100X catalytic domain that contributed
to generation of the hyperactive SB100X transposase2. These
comprise RKEN214–217DAVQ (ref. 27), M243H, and T314N
(Fig. 3). We find that N314 is exposed on the TCC surface, where
the mutation can improve transposase solubility, which has been
shown to be a limiting factor for transposition2. H243 is situated
next to the second catalytic residue D244 (Fig. 3b) and establishes
a parallel-displaced p-stack with H249, structuring the 243–251
loop and helping to position D244 in the active site. Finally,
residues 214–217 are located on the beginning of helix a1,
immediately following the loop connecting b3 to a1 (aa
209–214), which forms part of the target-binding groove
(Fig. 3c). D214 and Q217 side chains form hydrogen bonds
with main chain atoms in b3 and a1, intimately connecting these
elements and stabilizing the connecting loop conformation.
Simultaneously, A215 and V216 form hydrophobic interactions
with residues in the neighbouring a3 helix, positioning the loop
on the target-binding surface. Thus, the 214–217 mutations have
likely helped shape and ideally position the b3–a1 linker to
interact with the tDNA at the rim of the binding groove.
In addition, the structure offers a rationale for other previously
reported hyperactive mutations that are not present in
SB100X. For example, the ALHKID205–210KLVRIE mutations27
probably have a similar effect on the b3–a1 loop as the
RKEN214–217DAVQ mutation; the M243Q mutation in SB11
(ref. 25) likely stabilizes the active site the same way as M243H;
while surface mutations (for example, V253H, V255R25, T295N2
and D260K26) improve transposase solubility.
Structure-based design of tDNA interaction mutants. Next, we
used our TCC model to map transposase residues that may be
involved in tDNA-binding (green in Fig. 4a–c), and tested the
effect of their mutations in transposition assays (Fig. 4d and
Supplementary Fig. 4). Overall, we selected two sets of amino
acids for mutation: (i) amino acids located near the integration
site that may be involved in TA recognition and/or tDNA
bending (K186 and H187; Fig. 4b, dark green); and (ii) residues
that are likely involved in unspecific tDNA binding on the flanks
of the integration site (I212, N245, K252 and Q271; Fig. 4c, light
green); then, we designed mutants to either abolish the predicted
function of these residues or to generate a hyperactive phenotype.
In the first set, K186 and H187 localize to the end of the clamp
loop, which delves into the major groove of the tDNA substrate in
our TCC model and might contribute to broadening the groove
b
c
tDNA
TIR TIR
a
tDNA
3′OH
3′OH
Figure 2 | The SB TCC model. (a) Cartoon representation of the model: SB100X dimer (blue), tnp ends (TIRs, grey) and bent tDNA substrate
(tDNA, dark grey). (b) Surface representation of the tDNA-binding groove coloured by electrostatic potential calculated using APBS48 at 150mM salt.
The kinked tDNA (grey cartoon) fits well in the positively charged groove. Pink balls represent the 30OH groups of the tnp TS. (c) The tDNA
(stick representation with atomic colouring) scissile phosphates approach the active sites of the TCC.
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and/or kinking the tDNA substrate via unstacking bases at the
integration site (Fig. 4b). In Mos1, R186 was proposed to be
essential for target recognition and its alanine mutation abolished
integration7. Interestingly, the equivalent K186S mutation in
SB100X does not affect transposition (Fig. 4d), indicating that the
K186 side chain is not directly responsible for integration
site recognition in SB, while the K186E mutation abolishes
transposition (P¼ 10 4; t-test) confirming that proximity of this
protein segment to DNA is essential. In addition, we find that
mutations of H187 also affect transposition: introduction of an
aspartate (H187D) abolishes transposition (Po10 5; t-test),
while aromatic residues (H187F/Y)—that can function well in
tDNA bending—support activity and even exhibit hyperactive
phenotypes (P¼ 0.069 and 0.19 based on t-test for F and Y,
respectively) relative to SB100X. This suggests that in SB, H187
(rather than K186) might fulfil a function in target recognition by
side chain specific interactions with tDNA bases at the integration
site in a way similar to R186 in Mos1.
Our second set of mutants (I212, N245, K252 and Q271)
localizes to the surface of the catalytic domain within the tDNA-
binding groove (Fig. 4c,d). For Q271, the TCC model suggests
that its side chain directly contacts the tDNA backbone and helps
target binding. In agreement, both Q271S and Q271E mutants
exhibit reduced transposition (P¼ 0.21 ando10 4, respectively;
t-test). N245 forms a hydrogen bond with S270 and helps
position the loop that contains Q271. Consistently, the N245S
mutant is also practically inactive (P¼ 0.0022; t-test). In turn,
K252 is situated on the verge of the tDNA-binding groove fairly
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Figure 3 | SB100X structure explains previous hyperactive mutations. (a) The TCC model with catalytic domain residues mutated for the generation of
SB100X shown in yellow. The localization of the interactions shown in (b,c) is indicated by red and orange rectangles, respectively. (b) H243 stabilizes the
catalytic core (red) via p-stacking with H249 (indicated with dashed lines). (c) Residues 214DAVQ217 stabilize a flexible loop (including I212) and tether it
to the tDNA-binding surface. Dashed lines indicate hydrogen bonds.
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Figure 4 | Structure-based mutagenesis maps tDNA binding and generates novel hyperactive transposases. (a) TCC model with predicted tDNA-
binding residues selected for mutagenesis. (b,c) Zoom-ups on residues predicted to be involved in tDNA recognition or bending (dark green, b) and
residues lining the target-binding groove (light green, c). (d) Transposition assay for the mutants in HeLa cells. P values (based on one-sample t-test):
K186R, 0.93; K186S, 0.22; K186E, 0.0019; H187Y, 0.069; H187D, 6.9 10 6; Q271S, 0.21; Q271E, 7.5 10 5; N245S, 0.0022; K252S, 0.68; K252E, 0.042;
I212S, 0.0047; and I212T, 0.27. D3 indicates the negative control with the inactive E279D transposase. (e) Excision assays with the hyperactive I212S
transposase in vivo and in vitro (monitoring cleavage on both DNA strands: NTS, TS). Results are normalized to SB100X. All error bars represent the s.e.m.
for three independent experiments.
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distant from the tDNA position predicted by our model, so that
its positive charge might contribute to the overall DNA affinity,
but is not directly involved in tDNA recognition. In agreement,
the K252S mutation has no effect and only the K252E mutation
reduces transposition (P¼ 0.042; t-test). Finally, I212 is located
on the b3–a1 loop next to the DAVQ stretch (Fig. 3c) near the
tDNA. While its position is ideal for tDNA binding, its
hydrophobic side chain prohibits such contacts. Thus, to allow
for direct DNA contact and increase tDNA affinity, we mutated
I212 to short hydrophilic residues. We find that the I212S mutant
transposes 30% more efficiently than SB100X (P¼ 0.0047; t-test).
Since the transposon excision activity of I212S is unaltered in vivo
and in vitro (Fig. 4e and Supplementary Fig. 5), the observed
hyperactive phenotype is likely due to increased tDNA affinity as
predicted from the structure.
Discussion
The most surprising feature of the SB100X catalytic domain
structure concerns the clamp loop, which is inserted within the
RNaseH-fold of Tc1/mariner transposases. Unlike in previous
structures of Mos1 and SETMAR/Metnase7,32,33, in SB100X the
clamp-loop assumes an unusually bent conformation and creates
a large symmetric intermolecular interface connecting two
catalytic domains. Although this interaction might be provoked
by protein truncation or crystal packing, its extended size and low
DG argue for a significant functional relevance29. In accordance,
disrupting the interface by mutagenesis diminishes transposition
in cell-based transposition assays (Fig. 1d,f).
Concerning a potential functional role of the interaction, it is
unlikely to represent a PEC assembly, because the arrangement of
the catalytic domains is too compact to allow DNA to access the
active sites (Fig. 1b). However, accumulating biochemical data
indicate that Tc1/mariner transposases form multiple conforma-
tionally distinct dimeric states throughout their transposition
pathway7,8,13–15, and the dimeric assembly observed here could
represent one of the proposed DNA-free or single end-bound
pre-catalytic states, which must still undergo conformational
rearrangement upon PEC formation (see arrow in Fig. 1b). The
auto-inhibited dimer arrangement proposed by our SB100X
structure would offer two distinct benefits for the Tc1/mariner
transposition pathway. First, it could facilitate recruitment of a
sufficient number of transposases to the distantly located
transposon ends in the genome, thereby facilitating PEC
assembly without introducing futile DNA breaks. Second, as it
closely resembles the PEC, it would alleviate the need for major
conformational changes upon PEC assembly. The conformational
rearrangement required for activation would only entail a simple
rotation of one catalytic domain (Fig. 1b, B50 swing to with a
B20 backwards rotation) and repositioning of the flexible clamp
loop, which can likely occur easily without requiring significant
energy. In addition, for SB in particular such a pre-catalytic dimer
might also help facilitate transposase recruitment to the tnp ends
via the second transposase binding site in the TIR that has been
shown to be required for efficient transposition but is never
cleaved. Thus, the assembly observed here could also be a unique
feature of SB contributing to its exceptional efficiency.
The proposal that the interaction observed between the
SB100X catalytic domains in the crystals represents a functionally
relevant transposase dimer is further supported by the fact that
the b-strand interaction observed between the clamp loops and
the linkers of the two transposase subunits resembles the inter-
subunit interactions in the Mos1 PEC, which play an important
role in PEC assembly and coordination7. However, the molecular
details of the interactions are different: in the Mos1 PEC they
involve only one b-strand of the clamp loop (aa 168–172) and the
first b-strand of the linker (aa 113–116), while in the SB100X
structure the interaction extends to the second b-strand of the
clamp loop (aa 173–176) and involves a different part of the
linker (aa 119–122) (Fig. 1e). Remarkably, residues 119–122
belong to a highly conserved sequence stretch (KKPLLS) in
Tc1-like elements that is structurally equivalent to the WVPHEL
motif of mariner transposases, which has been shown to play a
critical role in orchestrating cleavage events within the
transpososome15,16,30. This suggests that different Tc1/mariner
transpososomes might use similar molecular strategies involving
the same flexible protein segments (that is, the clamp loop and
the linker) to exhibit multifaceted regulatory functions during
their transposition pathway and the interaction observed here
might represent an important regulatory state.
Molecular modelling and cell-based mutagenesis data pre-
sented here indicate that the SB100X transposase uses a bent
tDNA for integration. This is in good agreement with previous
work on various Tc1/mariner elements9,17–21, implying that
tDNA bending is a widespread feature within this superfamily. In
addition, strand transfer complex structures of more distantly
related DDE enzymes, the Mu phage transposase (MuA) and the
PFV integrase, indicated that tDNA bending is conserved more
broadly, likely serving to drive transposition forward by rendering
strand transfer irreversible via straining the DNA such that it
snaps away from the active sites after integration22,23. However,
available crystal structures revealed a remarkable diversity of
transpososome architectures and the degree of tDNA bending
used by individual systems seems to differ greatly. For instance,
the Tn5 transpososome performs integration with a 9-bp stagger
from the two opposite sides requiring little, if any, tDNA
bending34. In turn, PFV introduces a B90 bend in the target
with a single kink in the middle that is attacked by the two ends
of the viral DNA from the same side with a 4-bp stagger. Finally,
MuA introduces two kinks and a significant unwinding to bend
the tDNA sharply (B140) for integration with a 5-bp stagger.
In SB100X, the positively charged groove created by the
transposase catalytic domains in the TCC model accommodates a
B90 bent tDNA (from the PFV intasome) well (Fig. 2b), and
mutagenesis data supports this docking (Fig. 4). Although this
model approximates how tDNA might be bound in general, we
suspect that further kinks or unwinding will occur around the
target TA. Additional bending, perhaps similar to the one
observed in the Mu transpososome (P-P distance 24.5 Å on a 2 bp
step flanking the cleavage site)22, would help increase the distance
between the scissile phosphates (only 19.1 Å apart in the PFV
tDNA) improving their positioning in the active sites (that are
24.8 Å apart, measured on the 30OH groups of the TS, Fig. 2c).
This idea is consistent with the hyperactive phenotypes of the
H187 F/Y mutants, which likely help improve tDNA bending.
One of the unique features of the SB transposase compared
with better-characterized relatives like Mos1 and HsMar1 is the
Tc1 subfamily specific glycine-rich strip at the base of the clamp
loop. The structural data presented here proposes two distinct
functions for this motif. Firstly, owing to its flexibility, it might be
critical to the formation of a pre-catalytic transposase dimer,
thereby helping to control the pathway of transposition. Secondly,
as the glycine-rich strip is located close to the TA target site in the
TCC, its ‘naked’ peptide bonds could insert in the major groove,
helping to bend the tDNA. Although supported by the data
presented here, these proposals have to be validated through
experimental analysis of the complete SB TCC structure.
The SB transposon is a versatile genetic tool offering
widespread applications for genetic manipulations in research
and medicine. Although the SB transposase has been mutagen-
ized extensively2,25–27, rational design of improved variants has
not been possible so far in lack of structural and mechanistic data.
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The structure of the SB100X catalytic domain determined here
opens up avenues for structure-based engineering of designer SB
variants. For example, it might be possible to further enhance
transposase activity or increase/modulate target site specificity.
Hyperactive variants could further enhance gene transfer rates
greatly facilitating gene therapy applications. Increasing target
specificity would additionally improve the fidelity of this genetic
tool, providing an added benefit in medical applications.
Alternatively, it might be possible to create variants with
uncoupled excision and integration activities. The utility of
such tools e.g., in stem cell engineering has been already
demonstrated for piggyBac35,36, but they might also help
increase the specificity of target site selective SB-variants37.
In summary, the work presented here describes the atomic
resolution structure of the SB100X transposase catalytic domain
and shows that it provides a useful resource for transposase
engineering. Using the structure we create a model of the
complete transpososome with target DNA bound and map
transposase residues involved in tDNA binding. By mutational
analysis we validate the transpososome architecture and generate
two variants with efficiencies higher than SB100X, demonstrating
that structure-based design can enable the creation of further
hyperactive or designer SB transposases for genetic engineering.
Methods
Protein production and purification. The full-length SB100X transposase, its
catalytic domain, and the full-length I212S mutant were expressed recombinantly
and purified for in vitro biochemical assays and crystallization. The full-length
SB100X gene2 was first cloned into BspHI (50-GATCTCATGATGGGAAAATC
AAAAGAAATCAGCC-30) and XhoI (50-GATCCTCGAGCTAGTATTTGGTAG
CATTGCC-30) sites of the pETM22 (PepCore, EMBL Heidelberg) vector and the
I212S mutation was then introduced via site-directed mutagenesis. The SB100X
catalytic domain construct (aa 114–340) was generated via restriction-free cloning
into pETM22 (fw: 50-GGAAGTTCTGTTCCAGGGGCCCAGCGGCCACTCAGC
AAGG-30 and rev: 50-CGGATCCGGTACCTCATTAGTCCATCTAGTATTTGG
TAGCATTGCCTTTA-30). All proteins were expressed with an N-terminal
ThioredoxinA (TrxA)-6xHis-tag in Escherichia coli RosettaII(DE3)* cells
(Novagen) in LB medium at 16 C for 18 h. The fusion proteins were purified
on a Ni2þ -Sepharose column (in 1 PBS, 1M NaCl, 5% (v/v) Glycerol,
20mM Imidazole, 0.2mM TCEP) following the manufacturer’s instructions
(GE Healthcare). The eluate was incubated with PreScission protease (PepCore,
EMBL Heidelberg) for 18 h at 4 C to remove TrxA-6xHis. The cleaved tag was
removed by Ni-affinity purification and the protein was further purified by
size-exclusion chromatography on a Superdex 200 16/60 column (GE Healthcare)
in 1 PBS, 1M NaCl, 5% (v/v) Glycerol, 1mM MgCl2 and 0.2mM TCEP.
DNA oligonucleotides. DNA oligonucleotides were purchased PAGE-purified
from Integrated DNA Technologies. The 52 nt dsDNA substrate used for in vitro
cleavage assays was generated via 50-labelling of individual oligonucleotides
(50-GAGCTCGGTACCCTATACAGTTGAAGTCGGAAGTTTACATACACTTA
AGTTG-30 or 50-CAACTTAAGTGTATGTAAACTTCCGACTTCAACTGTATA
GGGTACCGAGCTC-30) with 32P before annealing.
Crystallization and structure determination. Two microlitre (ml) of the purified
SB100X catalytic domain (aa 114–340) at 19mgml 1 (in 20mM Hepes (pH 7.2),
50mM NaCl, 2% (v/v) Glycerol, 10mM MgCl2, 0.2mM TCEP) were mixed with
2 ml of precipitant solution (0.1M NaCitrate pH 4.8, 3.2M (NH4)2SO4). Crystals
grew within 5 days at 4 C in hanging drop vapour diffusion plates and were flash
frozen in liquid nitrogen after addition of 5% glycerol as cryo-protectant. X-ray
diffraction data were collected at 100 K at 0.9763Å wavelength on the PETRAIII
beam line P14 (EMBL/DESY, Hamburg, Germany). Diffraction images were
processed and scaled using XDS38 and XSCALE39. The structure was solved by
molecular replacement in Phaser40 using the catalytic domain of Mos1 (from PDB
ID 3HOS)7 as search model. The solution was refined through iterative cycles of
model building in COOT41 and refinement in Phenix42 and was validated using
MolProbity43 (Table 1). The final structure has very good geometry with 98% of
protein residues in favoured Ramachandran regions and no outliers.
Modelling. For modelling the SB TCC structure, a homology model was generated
for the full-length SB100X transposase in I-TASSER44 based on the coordinates of
the Mos1 PEC7 (PDB ID 3HOS) using the coordinates of the here determined
catalytic domain structure as restraint. Since I-TASSER generated small alterations
in the catalytic domain coordinates relative to the actual structure, the catalytic
domain coordinates were then replaced with the ones from the structure except for
the clamp loop and the linker (the conformation of which is expected to change
upon PEC formation), where the model coordinates were used. The arrangement of
two transposase monomers and the positioning of the tnp end DNA in the
complex was derived from superposition with the Mos1 PEC7. The bent tDNA
substrate was taken from the PFV intasome structure (PDB 3OS1)23 and manually
docked into the tDNA-binding groove generated by the two SB catalytic domains.
For docking, the distance between the 30OH of the tnp ends and the scissile
phosphates in the tDNA were restrained to 5Å. Manual modelling operations were
performed in Chimera45 and Pymol46, and molecular graphics were generated in
Pymol.
In vivo transposition assays. Overall SB transposition activity was quantified in
HeLa cells (ATCC Cell Lines) using the protocol described in1 that was fine-tuned
to obtain single-copy insertions. In short, transposon donor plasmids containing a
resistance-encoding transposon (pT2Bpuro) were co-transfected with plasmids
encoding the full-length SB100X or mutated SB100X transposase variants
(pCMV(CAT)T7-SB100X). The catalytically inactive mutant, E279D (referred to as
D3)2 was used as negative control. 48 h after transfection, cells were trypsinized and
selected for transposon integration using 3 mgml 1 puromycin (InvivoGen).
Surviving colonies were fixed, stained with methylene blue and counted. At least
three independent experiments were performed for every mutant. All data points
were averaged and standard errors were calculated using a James–Stein-shrinkage
estimator of the corresponding variances47. To evaluate statistical significance,
two-tailed one-sample t-test was performed.
Expression of mutant proteins was tested via western blotting 48 h after
transfection. Cells were lysed and proteins were extracted via sonication at
4 C. Total protein was quantified using a BCA Protein Assay Kit (Pierce)
and 10 mg per lane were loaded onto 10% polyacrylamide gels and subjected to
SDS–polyacrylamide gel electrophoresis. Gels were transferred to nitrocellulose
membrane (Hybond ECL, Amersham Bioscience, Little Chalfont, UK) and
immunoblotting was performed according to standard procedures. Bands were
detected with anti-SB (R&D Systems; Catalog Number AF2798; dilution 1:5,000) or
anti-Vinculin (Abcam; Catalog Number ab18058; dilution 1:3,000) antibodies,
visualized with chemiluminescent reagents (ECL Prime Western Blotting Detection
Kit, Amersham Bioscience) and imaged on films (Hyperfilm ECL High
performance, Amersham Bioscience). Correct localization of the mutant proteins
was confirmed by immunofluorescence staining. Cells were fixed with 4% PFA
in PBS 48 h post transfection, incubated with anti-SB (R&D Systems) primary
antibody and stained with Alexa Fluor 488-labelled secondary antibody
(Life Technologies) and DAPI (Invitrogen). Cells were examined on a Nikon
Eclipse Ti-S inverted microscope (40x objectives).
In vivo excision assays. SB’s excision activity was quantified using a fluorescence-
activated cell sorting (FACS)-based excision assay in HeLa cells (ATCC Cell Lines;
Supplementary Fig. 5c). To this aim, plasmids expressing SB100X (above) were
transfected together with a tnp donor plasmid (pCMV(CAT)-GFP//T2Neo).
The transposon donor contained a green fluorescent protein (GFP) open reading
frame disrupted by a SB tnp insertion carrying a neomycin (neo) resistance gene.
Precise excision of the transposon restores the GFP open reading frame leading
to fluorescent cells that can be detected by FACS analysis to quantify excision
frequencies. A GFP-expressing SB tnp plasmid (pT2.CAGGS.AmGFP) was used as
control. Three days post-transfection cells were trypsinized, washed with PBS, fixed
with 1% PFA in PBS and FACS analysed with a BD LSR II flow cytometer
(BD Biosciences). Data were evaluated with FCS Express 4 Flow Cytometry
(De Novo Software). Excision frequencies determined for mutated SB100X variants
were normalized against the values measured for the SB100X protein.
In vitro cleavage assays. SB100X or the I212S mutant were mixed with LO52
(20 nM) at a molar ratio of 10:1 in 20mM Hepes (pH 7.2), 150mM NaCl, 10mM
MgCl2 and 1mM DTT. Reactions were incubated at 25 C for 20 h and terminated
by Proteinase K (New England Biolabs) treatment according to the manufacturer’s
instructions. Reaction products were ethanol-precipitated, re-suspended in
2 formamide loading dye and analysed by gel electrophoresis on TBE-urea
12% acrylamide/bis-acrylamide (19:1) gels. Gels were imaged on a FLA 7000
phosphoimager (Fuji) and quantified in the Fujifilm Multi Gauge software package.
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